Becton, Dickinson and Company (NYSE:BDX – Free Report) had its target price upped by Bank of America from $185.00 to $200.00 in a research report sent to investors on Monday morning,Benzinga reports. They currently have a neutral rating on the medical instruments supplier’s stock.
A number of other equities analysts have also recently weighed in on the company. Evercore set a $180.00 price target on Becton, Dickinson and Company in a report on Monday, July 6th. Weiss Ratings reissued a “sell (d+)” rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. TD Cowen boosted their price objective on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. Wells Fargo & Company increased their target price on Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Finally, Stifel Nicolaus set a $195.00 price target on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Hold” and a consensus price target of $187.67.
View Our Latest Stock Report on Becton, Dickinson and Company
Becton, Dickinson and Company Stock Up 0.2%
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the prior year, the firm posted $3.68 earnings per share. The company’s revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, research analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current year.
Becton, Dickinson and Company Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is presently 126.51%.
Insider Transactions at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the sale, the executive vice president owned 13,172 shares of the company’s stock, valued at $1,918,633.52. The trade was a 7.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 9,105 shares of company stock valued at $1,590,208 in the last 90 days. 0.40% of the stock is owned by company insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of BDX. Brighton Jones LLC raised its stake in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Becton, Dickinson and Company by 4.4% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 627,900 shares of the medical instruments supplier’s stock valued at $122,403,000 after purchasing an additional 26,671 shares during the last quarter. Cooke & Bieler LP grew its holdings in shares of Becton, Dickinson and Company by 27.2% during the fourth quarter. Cooke & Bieler LP now owns 1,126,471 shares of the medical instruments supplier’s stock valued at $218,614,000 after purchasing an additional 240,673 shares during the last quarter. Northside Capital Management LLC raised its position in shares of Becton, Dickinson and Company by 18.3% during the 2nd quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier’s stock worth $9,280,000 after purchasing an additional 9,494 shares during the period. Finally, Wealthfront Advisers LLC bought a new stake in shares of Becton, Dickinson and Company in the 2nd quarter worth approximately $2,567,000. 86.97% of the stock is owned by hedge funds and other institutional investors.
About Becton, Dickinson and Company
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Featured Stories
- Five stocks we like better than Becton, Dickinson and Company
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
